Review anchor
Aldo-keto reductase family 1 member C2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Aldo-keto reductase family 1 member C2
CHEMBL5847
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Aldo-keto reductase family 1 member C2 as ChEMBL target CHEMBL5847, mapped to UniProt P52895. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL5847
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P52895
Aldo-keto reductase family 1 member C2
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Aldo-keto reductase family 1 member C2 matters
Aldo-keto reductase family 1 member C2 is reviewed as Aldo-keto reductase family 1 member C2 (UniProt P52895); the current evidence base includes 10 approved drugs, 688 compounds, and 75 assays, with lead potency reaching pChEMBL 8.8.
Protein context
Aldo-keto reductase family 1 member C2
Aldo-keto reductase family 1 member C2 Sequence length is 323 aa.
Review this target as Aldo-keto reductase family 1 member C2, mapped to UniProt P52895. Sequence length is 323 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P52895
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 10 approved drugs, 688 compounds, and 75 assays for this target. The dominant activity type is IC50. CHEMBL1275725 is the current potency anchor at pChEMBL 8.8.
Use CHEMBL1275725 as the tractability anchor when discussing potency (pChEMBL 8.8).
Activity source · ChEMBL 36 via Core Engine
10 approved
pChEMBL 8.8
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Aldo-keto reductase family 1 member C2 matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P52895, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
688
Total Compounds
75
Total Assays
10
Approved Drugs
IC50: 643.0, KI: 35.0, KD: 1.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL1275725
|
8.8 | Ki | — |
|
|
No preferred name
CHEMBL1277647
|
7.8 | Ki | — |
|
|
No preferred name
CHEMBL2323507
|
7.8 | IC50 | — |
|
|
No preferred name
CHEMBL1275704
|
7.8 | Ki | — |
|
|
No preferred name
CHEMBL1275703
|
7.7 | Ki | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
FLURBIPROFEN
CHEMBL563
|
1986 |
|
|
MEFENAMIC ACID
CHEMBL686
|
1967 |
Source Header